

Index

a

- absolute protein expression (APEX) 31
- ACCE (analytic validity, clinical validity, clinical utility, and ethical, legal, and social implications) wheel 101
- activated leukocyte cell adhesion molecule (ALCAM) 189
- aerosol 79
- alkaline phosphatase (ALP) 111
 - bone-specific (BAP) 115
- alphafetoprotein (AFP) 196
- analytical method 63
 - validation 44f., 100
- anaplastic lymphoma kinase (ALK) gene 214
- antibody
 - therapeutic 15f.
- APEX, *see* absolute protein expression
- area under curve (AUC) 30, 100, 220
- assay
 - insertion point 62
- ataxia telangiectasia (AT) 153
- autoantibody 156

b

- BAP, *see* bone-specific alkaline phosphatase
- biobanking 50, 238
 - biomarker validation 238
- biological diversity 235ff.
- biomarker 1ff.
 - assay 197
 - bone health in CVD 112
 - breast 149ff.
 - breath 86
 - classification 208
 - clinical qualification of candidate biomarker 47
 - clinical study 210
 - clinical validation 207ff.
 - commercial assay 195
 - commercialization 183ff.
 - confounder 83
 - disease 3ff., 193, 208
 - drug research 9f.
 - expression 64
 - identification 63
 - implementation in clinical study 221
 - limitation 154
 - multivariate index assay 16
 - performance characterization 48
 - platform 184
 - provider 54
 - qualification 39ff., 53
 - reference range for candidate biomarker 46
 - single marker 153
 - tissue 151ff.
 - translational use 209
 - type 11, 41
 - validation 194, 218, 231ff.
 - verification 234f.
- biomarker development 13
 - challenges 157
 - methodological consideration 47
 - quantitative proteomics technique 23ff.
- biomarker discovery 170ff., 183, 233ff.
 - bottom-up proteomics technique 24f.
 - future target 156
 - medical diagnostic imaging 59ff.
- biomarker selection 61
 - imaging 61
- biomarker test 17
 - evaluation 99
 - validation 99
- biomarker test validation 12
- biomarker-enrichment design 215

- biomarker-stratified design 215
- biopharmaceuticals 18
- biorepository 222, 240
- blood urea nitrogen (BUN) 217
- body fluid analysis 150ff.
- bone health
 - biomarker in CVD 112ff., 126
- bone marrow (BM) 110
- bone mineral density (BMD) 107ff.
- bone morphogenetic protein (BMP) 122
- bone remodeling biomarker 107ff.
- bone-specific alkaline phosphatase (BAP) 115
- BRCA1 152
- BRCA2 152
- breast
 - imaging 148
 - physical examination 148
 - pregnancy-associated 157
 - ultrasound 148
- breast cancer 147
 - detection 149
 - treatment 150ff.
 - treatment effect 155
- breast cancer biomarker 150, 195
 - identification 147ff.
 - validation 147ff.
- breast disease
 - benign 157
- breath 75ff.
 - analytical tool 80
 - biomarker 86
 - exhaled gas 79
 - sampling technique 80
- breath analysis 76ff.
 - breath sampling for offline analysis 84
 - discovery 81f.
 - online breath sampling and direct analysis 84
 - sampling impact 83
 - study 77ff.
 - targeted study approach 81f.
- BUN, *see* blood urea nitrogen

c

- c-Kit (CD117) 195
- C-reactive protein (CRP) 40, 237
- CAD, *see* coronary artery disease
- cancer biomarker 2, 189ff.
- candidate biomarker 46f.
- capnography 86
- carcinoembryonic antigen (CEA) 159, 196
- cardiac troponin (cTn) complex 40

- cardiovascular disease (CVD) 5, 107ff.
 - biomarker of bone health 112
- cathepsin K (CatK) 112f.
- CER, *see* comparative effectiveness research
- CID, *see* collision induced dissociation
- chemical induction 65
- chronic kidney disease (CKD) 108
- CK-MB, *see* creatine kinase-MB
- clinical biomarker 214
- clinical data
 - sample annotation 52
- clinical development
 - safety marker 216
- clinical pharmacology 14
- clinical proteomics 9
- clinical study 240
 - biomarker 210
 - regulatory considerations for implementation 221
- clinical trial status 193
- clinical validation 207
- cOC, *see* osteocalcin
- collagen type 1 cross-linked C-telopeptide (CTx) 122
- collision induced dissociation (CID) 165
- comparative effectiveness research (CER) 97
- computed tomography (CT) 60
- condensate 79
- confirmatory clinical study 214
- context of use (CoU) 48
- contract research organization (CRO) 39ff., 54
- coronary artery disease (CAD) 115ff.
- creatine kinase-MB (CK-MB) 40
- cTn, *see* cardiac troponin complex
- CTx, *see* collagen type 1 cross-linked C-telopeptide
- curse of dimensionality 173
- CVD, *see* cardiovascular disease

d

- data-dependent acquisition (DDA) 163ff.
- data-independent acquisition (DIA) 163
 - MS 169
- DDT, *see* drug development tool
- desphospho-carboxylated matrix Gla protein (dp-cMGP) 123
- desphospho-uncarboxylated matrix Gla protein (dpu-cMGP) 123
- diabetes 117ff.
- diagnostic biomarker 13
- difference gel electrophoresis (DIGE) 27ff.
 - two-dimensional (2D-DIGE) 27ff.

discovery-to-verification study 238
 disease 5, 64f.
 disease biomarker 3ff., 208, 231
 disease heterogeneity 62, 239
 disease-associated biomarker 193

DNA

– biomarker 7
 DNA analysis
 – breast cancer 158
 DNA candidate 159
 DNA methylation 157
 Down syndrome 237
 drug development tool (DDT) 43ff.
 drug research
 – biomarker 9f.
 ductal lavage 158

e

early patient study 211
 EBA, *see* exhaled breath aerosol
 EBC, *see* exhaled breath condensate
 EbM, *see* evidence-based medicine
 electrochemical sensor 80
 electrophoresis
 – two-dimensional (2-DE) 27
 ELISA (enzyme-linked immunosorbent assay) 42, 63, 187, 235ff.
 enrichment design 215
 epidermal growth factor receptor (EGFR)II 152
 ESI (electrospray ionization) 165, 185
 estrogen receptor (ER) 151, 195
 ethics 222, 235
 – sample 53, 223
 evaluation
 – biomarker test 99
 evidence-based medicine (EbM) 97
 exhaled breath aerosol (EBA) 79
 exhaled breath condensate (EBC) 79
 experimental model 64
 exposome 85

f

fibroblast growth factor 23 (FGF-23) 116
 fit-for-purpose approach 45
 fluorodeoxyglucose (FDG) 59
 functional genomics 8

g

gene panel
 – biomarker in tissue 154
 genetic factor 123
 genetic manipulation 65

genomics 8
 – biomarker validation 231
 glycoproteomics 187
 grafting 66

h

health technology assessment (HTA) 95ff.
 – personalized medicine technology 95ff.
 healthy volunteer study 210
 heart transplantation 237
Helicobacter pylori 86
 hepatitis C virus (HCV) 189
 Heregulin (HER)2 152
 – receptor 216
 – HER-2/neu 195
 high level of homocysteine (HHcy) 110
 homocysteine (Hcy) 107
 hsCRP (high-sensitivity C-reactive protein) 115
 HTA, *see* health technology assessment
 human disease 64f.
 human rhinovirus (HRV) 88

i

ICAT (isotope coded affinity tag) 32, 170
 ICPL (isotope-coded protein labeling) 32
 ICTP (cross-linked carboxy-terminal telopeptide of type I collagen) 122
 Illumina dye sequencing 192
 image processing 70
 imaging 61
 – biomarker selection 61
 imaging biomarker 3
 immunochemistry platform 81
in vitro diagnostic multivariate index assay (IVDMIA) 17
in vivo model 68
 inflammatory marker 156
 inorganic breath biomarker 86
 Ion Torrent 192
 isotope coded affinity tag, *see* ICAT
 isotope-coded protein labeling, *see* ICPL
 iTRAQ (isobaric tag for relative and absolute quantification) 32, 170

j

Janus kinase (JAK) inhibitor INCB 18424 211

k

Ki67 152
 kidney toxicity 41
 knockout mutation 65

I

label-based proteome analysis 31
 label-free protein quantification 30
 laboratory diagnostics 12
 laboratory proficiency 46
 laboratory-based mass spectrometry 81
 laboratory-developed test (LDT) 17
 level of evidence (LoE) 98
 lipid
 – biomarker 7
 lipopolysaccharide (LPS) 66
 liquid chromatography (LC) 165
 liquid chromatography mass spectrometry (LC-MS) 81, 163
 liver functionality 40

m

magnetic resonance imaging, *see* MRI
 MALDI (matrix-assisted laser ionization desorption) 165, 185
 – mass spectrometry imaging (MALDI MSI) 33ff.
 MALDI TOF mass spectrometer 33
 Mammaprint 152
 mammography 148
 mass analyser 30
 mass spectrometry (MS)
 – coupled to liquid-chromatography (LC-MS) 81, 163
 – data-independent acquisition (DIA) 169
 – laboratory-based 81
 – online 80
 – tandem (MS/MS) 31, 165ff., 237
 mass spectrometry-based proteomics 29ff., 163ff.
 – ionization method 29
 medical diagnostic imaging 59ff.
 – biomarker discovery 59ff.
 metabolite
 – biomarker 7
 method validation 219
 micro system 67
 Microarray 235
 microRNA (miRNA) 193
 minimum information about a proteomics experiment (MIAPE) 239
 model species 64
 MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) 64
 MRI (magnetic resonance imaging) 60, 149
 MS, *see* mass spectrometry
 multidimensional protein identification technology (MudPIT) 164ff.
 multiple reaction monitoring (MRM) 237

n

NAF (nipple aspiration fluid) 158
 negative model 64
 network analysis 163
 next-generation sequencing (NGS) 190
 NPV (negative predictive value) 100
 nitric oxide 86
 normalized spectral abundance factor (NSAF) 31
 nuclear imaging infrastructure 69

o

oncotype DX 152
 online mass spectrometry (MS) 80
 optical spectroscopy instrument 80
 organic breath biomarker 87
 orphan model 64
 osteocalcin (OC) 111ff.
 – carboxylated (cOC) 117
 – uncarboxylated (ucOC) 117
 osteopontin (OPN) 111ff.
 osteoporosis 107
 osteoprotegerin (OPG) 111ff., 123f.
 oxidative stress (OxS) 107
 oxidized low density lipoprotein (OxLDL) 111

p

p53 153
 p63 protein 195
 PAH, *see* polycyclic aromatic hydrocarbon
 PAI-1 (uPA inhibitor) 159
 personalized medicine paradigm 7
 personalized medicine technology
 – health technology assessment (HTA) 95ff.
 PET, *see* positron emission tomography
 pharmacodynamic (PD) biomarker 3ff., 207f.
 pharmacodynamics 9
 pharmacogenetics 14
 pharmacogenomics 14
 pharmacological induction 65
 phosphatase and tensin homolog (PTEN) 153
 physical induction 66
 PICP, *see* procollagen type I C-propeptide
 PIIINP, *see* procollagen type III N-propeptide
 PINP, *see* procollagen type I N-propeptide
 polar volatile organic compound (PVOC) 79
 polycyclic aromatic hydrocarbon (PAH) 76
 positive predictive value (PPV) 100

positron emission tomography (PET) 59
 – radiotracer 69
 post-translational modification (PTM) 186
 PPI, *see* protein–protein interaction network analysis
 PR, *see* progesterone receptor
 precision medicine 2
 preclinical analysis technique 67
 preclinical model 64ff.
 predictive biomarker 3ff., 213
 procollagen type I C-propeptide (PICP) 121
 procollagen type I N-propeptide (PINP) 121
 procollagen type III N-propeptide (PIINP) 121
 profiling 163
 progesterone receptor (PR) 151, 195
 prognostic biomarker 214
 prostate-specific antigen (PSA) 196
 protein
 – biomarker 7
 – label-free quantification 30
 protein analysis
 – breast cancer 158
 protein binding assay 235
 protein candidate 159
 protein standard absolute quantification (PSAQ) 171
 protein–protein interaction (PPI) network analysis 174f.
 proteome analysis
 – label-based 31
 proteomic data
 – evaluation 163ff.
 proteomics 231ff.
 – biomarker validation 231ff.
 – bottom-up technique 24f., 186
 – mass spectrometry-based 29ff., 163ff.
 – methodology 164
 PSA, *see* prostate-specific antigen
 PSAQ, *see* protein standard absolute quantification
Pseudomonas aeruginosa 88
 PTEN, *see* phosphatase and tensin homolog
 PVOC, *see* polar volatile organic compound
 pyrosequencing 191

q

qualification 43
 – biomarker 39ff., 53
 quantitative polymerase chain reaction (QPCR) 63

quantitative proteomics technique
 – biomarker development 23ff.

r

RA, *see* rheumatoid arthritis
 radiation
 – breast cancer 150
 radiotracer 67ff.
 receiver–operator characteristic (ROC)
 curve 87, 100, 220
 receptor activator of nuclear factor kappa-B ligand (RANKL) 110ff.
 region of interest (ROI) 70
 reverse phase protein microarray (RPMA) 189f.
 rheumatoid arthritis (RA) 209, 237
 RNA candidate
 RNA transcript
 – biomarker 7
 ROC, *see* receiver–operator characteristic
 ROI, *see* region of interest
 RPMA, *see* reverse phase protein microarray

s

safety marker
 – clinical development 216
 sample
 – annotation 52
 – breath 80ff.
 – circulating 158
 – clinical data 52
 – collection 50
 – ethical consideration 53, 223
 – quality 50
 – storage 51
 – type selection 158
 sclerostin 115
 SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) 27
 selected reaction monitoring, *see* SRM
 selective estrogen receptor modulator (SERM) 151
 sensitivity 49
 sequencing by oligonucleotide ligation and detection, *see* SoLiD
 serum creatinine (sCr) 217
 shotgun proteomics 165, 232
 signal intensity measurement 30
 signal transducer and activator of transcription (STAT)3 211
 SILAC (stable isotope labeling by amino acids in cell culture) 32, 170
 SILAM (stable isotope labeling by amino acids in mammals) 32

- single marker 153
 - single nucleotide polymorphism (SNP) 63
 - single-molecule real-time sequencing (SMRT) 192
 - SoLiD (sequencing by oligonucleotide ligation and detection) 192
 - specificity 49
 - SPECT (single photon emission computed tomography) 60
 - spectral count (SpC) approach 31, 170
 - normalization 172
 - spontaneous disease model 64
 - SPR, *see* surface plasmon resonance
 - SRM (selected reaction monitoring)
 - acquisition data 168, 237
 - stable isotope labeling by amino acids in cell culture approach, *see* SILAC
 - stable isotope labeling by amino acids in mammals, *see* SILAM
 - standard operational procedure (SOP) 234ff.
 - Staphylococcus aureus* 88
 - STAT3, *see* signal transducer and activator of transcription 3
 - stratification biomarker 208
 - surface plasmon resonance (SPR) 188
 - imaging 188
 - surgery
 - breast cancer 150
 - surrogate biomarker 3ff.
 - surrogate endpoint 208
 - systemic therapy
 - breast cancer 151
- t**
- T1DM, *see* type 1 diabetes
 - T2DM, *see* type 2 diabetes
 - tamoxifen 151
 - tandem mass spectrometry (MS/MS) 31, 165ff., 237
 - tandem mass tag, *see* TMT
 - target biomarker 208
 - targeted proteomics 168, 237
 - tartrate-resistant acid phosphatase 115
 - Thomsen–Friedenreich (TF) 159
 - tissue
 - biomarker 151ff.
 - tissue-derived marker 4
 - TMT (tandem mass tag) 32
 - toxicology biomarker 208
 - transgenic mouse 65
 - transition 169
 - tumor
 - primary 155
 - recurrent 155
 - tumor biomarker 16
 - tumor heterogeneity 154
 - tumor marker 6
 - type 1 diabetes (T1DM) 119
 - type 2 diabetes (T2DM) 117ff.
- u**
- ultrasound (US) 61
 - breast 148
 - ucOC, *see* osteocalcin
 - uPA inhibitor (PAI-1) 159
 - urinary kidney biomarker 217
 - urinary plasminogen activator (uPA) 159
- v**
- validation 43, 194, 218
 - analytical method 44
 - breast cancer biomarker 147
 - biomarker 231
 - biomarker test 99
 - challenges 157
 - clinical 207
 - clinical trial 240
 - genomics 231
 - guideline 45
 - proteomics 231
 - variability
 - extrinsic 14
 - intrinsic 14
 - variant of unknown significance (vus) 152
 - vitamin D (VitD) 120
 - 25(OH)-vitamin D (25(OH)D) 120f.
 - VitD receptor (VDR) 125
 - volatile organic compound (VOC)
 - endogenous 76
 - exogenous 76
- x**
- xenografts 66
- z**
- zero-mode waveguide (ZMW) 192f.